GT Biopharma (GB:0RU9)
UK Market

GT Biopharma Stock Analysis & Ratings

GB:0RU9 Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range€0.00 - €0.00
Previous CloseN/A
Average Volume (3M)N/A
Market CapN/A
P/E Ratio-11.1
Next EarningsMay 16, 2022
EPS Forecast-€0.29
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-2.28



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was €0.00 and its highest was €0.00 in the past 12 months.
    What is GT Biopharma’s market cap?
    Currently, no data Available
    What is GT Biopharma’s price target?
    The average price target for GT Biopharma is €20.40. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is €23.72 ,the lowest forecast is €17.08. The average price target represents N/A Increase from the current price of N/A.
      What do analysts say about GT Biopharma?
      GT Biopharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
        When is GT Biopharma’s upcoming earnings report date?
        GT Biopharma’s upcoming earnings report date is May 16, 2022 which is 2 days ago.
          How were GT Biopharma’s earnings last quarter?
          GT Biopharma released its earnings results on Mar 28, 2022. The company reported -€0.541 earnings per share for the quarter, missing the consensus estimate of -€0.187 by -€0.354.
            Is GT Biopharma overvalued?
            According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
              Does GT Biopharma pay dividends?
              GT Biopharma does not currently pay dividends.
              What is GT Biopharma’s EPS estimate?
              GT Biopharma’s EPS estimate is -€0.16.
                How many shares outstanding does GT Biopharma have?
                Currently, no data Available
                What happened to GT Biopharma’s price movement after its last earnings report?
                GT Biopharma reported an EPS of -€0.541 in its last earnings report, missing expectations of -€0.187. Following the earnings report the stock price went same N/A.
                  Which hedge fund is a major shareholder of GT Biopharma?
                  Currently, no hedge funds are holding shares in GB:0RU9


                  GT Biopharma Stock Analysis

                  Smart Score
                  Price TargetModerate Buy
                  The GT Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  GT Biopharma

                  GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.

                  Similar Stocks
                  Price & Change
                  Cyclacel Pharmaceuticals
                  OncoVista Innovative Therapies
                  Infinity Pharma
                  Eagle Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis